Compugen Ltd (CGEN) 6.95 $CGEN
Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program
PR Newswire - Wed Jun 22, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive therapeutic discovery company, today disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN-15029 target program. This antibody candidate is now undergoing preclinical development activities in preparation for advancement to clinical trials, with an anticipated IND filing next year. CGEN-15029 is one of multiple novel immune checkpoint targets discovered by the Company through the use of its unique in silico predictive discovery infrastructure.
CGEN: 6.95 (+0.16)
Shares of CGEN Up 24.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:30PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 23.95% as of today's recent price of $6.65.
CGEN: 6.95 (+0.16)
Compugen Has Returned 29.5% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Jun 02, 12:51AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 29.54% as of today's recent price of $6.95.
CGEN: 6.95 (+0.16)
Compugen to Present at the Jefferies Global Healthcare Conference in New York
PR Newswire - Mon May 23, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Jefferies Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016.
CGEN: 6.95 (+0.16)
Compugen Up 26.2% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Wed May 18, 12:57AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 26.19% as of today's recent price of $6.77.
CGEN: 6.95 (+0.16)
Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv
PR Newswire - Mon May 16, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Oppenheimer 17th Annual Israeli Conference in Tel Aviv, Israel on Sunday, May 22, 2016.
CGEN: 6.95 (+0.16)
Compugen Has Returned 31.1% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Tue May 10, 1:34PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.13% as of today's recent price of $7.04.
CGEN: 6.95 (+0.16)
Compugen reports 1Q loss
Automated Insights - Tue May 10, 6:14AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $8.6 million in its first quarter.
CGEN: 6.95 (+0.16)
Compugen Ltd. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the first quarter ended March 31, 2016.
CGEN: 6.95 (+0.16)
Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET
PR Newswire - Wed Apr 27, 6:15AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, May 10, 2016, to review the first quarter 2016 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.
CGEN: 6.95 (+0.16)
31.0% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Fri Apr 22, 12:44AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.03% as of today's recent price of $7.03.
CGEN: 6.95 (+0.16)
Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration With Bayer
PR Newswire - Mon Apr 18, 6:14AM CDT
Compugen Ltd. (NASDAQ: CGEN ), a leading predictive drug discovery company, announced today that it has achieved a first preclinical milestone for CGEN-15022 pursuant to its cancer immunotherapy collaboration with Bayer. The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.
CGEN: 6.95 (+0.16)
Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.
PR Newswire - Wed Apr 06, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today that Elliott Sigal, M.D., Ph.D., former Executive Vice President and Director of Bristol-Myers Squibb, has joined Compugen Ltd. as a strategic advisor. The Company also announced that Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center at Johns Hopkins University of Medicine, and Chairman of Compugen's Scientific Advisory Board, has in addition joined the Board of Directors of Compugen USA, Inc., Compugen Ltd.'s wholly-owned antibody discovery and development subsidiary.
CGEN: 6.95 (+0.16), BMY: 72.31 (+1.06)
Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston
PR Newswire - Mon Mar 28, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, will present an overview of the Company's immuno-oncology programs and underlying predictive discovery capabilities at the Jefferies 2016 Immuno-Oncology Summit in Boston, on Thursday, April 7, 2016.
CGEN: 6.95 (+0.16)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 73.07 (+0.50), BIOD: 0.33 (+0.02), CLBS: 0.52 (+0.03), ARGS: 5.46 (-0.14), AZN: 28.70 (+0.06), CGEN: 6.95 (+0.16), ATHX: 1.95 (-0.21)
Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results
PR Newswire - Tue Feb 09, 6:09AM CST
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the fourth quarter and year ended December 31, 2015.
CGEN: 6.95 (+0.16)
Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology Program
PR Newswire - Wed Jun 22, 6:09AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive therapeutic discovery company, today disclosed at the JMP Securities Life Science Conference in NY, COM701 as the lead monoclonal antibody therapeutic candidate for the Company's CGEN-15029 target program. This antibody candidate is now undergoing preclinical development activities in preparation for advancement to clinical trials, with an anticipated IND filing next year. CGEN-15029 is one of multiple novel immune checkpoint targets discovered by the Company through the use of its unique in silico predictive discovery infrastructure.
CGEN: 6.95 (+0.16)
Shares of CGEN Up 24.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 09, 1:30PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 23.95% as of today's recent price of $6.65.
CGEN: 6.95 (+0.16)
Compugen Has Returned 29.5% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Thu Jun 02, 12:51AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 29.54% as of today's recent price of $6.95.
CGEN: 6.95 (+0.16)
Compugen to Present at the Jefferies Global Healthcare Conference in New York
PR Newswire - Mon May 23, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Jefferies Global Healthcare Conference in New York, NY on Tuesday, June 7, 2016.
CGEN: 6.95 (+0.16)
Compugen Up 26.2% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Wed May 18, 12:57AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 3 months, Compugen has returned 26.19% as of today's recent price of $6.77.
CGEN: 6.95 (+0.16)
Compugen to Present at the Oppenheimer Annual Israeli Conference in Tel Aviv
PR Newswire - Mon May 16, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial and Operating Officer of Compugen, will present a corporate overview and update at the Oppenheimer 17th Annual Israeli Conference in Tel Aviv, Israel on Sunday, May 22, 2016.
CGEN: 6.95 (+0.16)
Compugen Has Returned 31.1% Since SmarTrend Recommendation (CGEN)
Comtex SmarTrend(R) - Tue May 10, 1:34PM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.13% as of today's recent price of $7.04.
CGEN: 6.95 (+0.16)
Compugen reports 1Q loss
Automated Insights - Tue May 10, 6:14AM CDT
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $8.6 million in its first quarter.
CGEN: 6.95 (+0.16)
Compugen Ltd. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:01AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the first quarter ended March 31, 2016.
CGEN: 6.95 (+0.16)
Compugen First Quarter 2016 Conference Call and Webcast Scheduled for Tuesday, May 10, 2016 at 10:00 AM ET
PR Newswire - Wed Apr 27, 6:15AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that the Company will host a conference call at 10:00 AM ET on Tuesday, May 10, 2016, to review the first quarter 2016 results. The quarterly results will be released on the Company's website (www.cgen.com) prior to the conference call.
CGEN: 6.95 (+0.16)
31.0% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Fri Apr 22, 12:44AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on March 2nd, 2016 at $5.37. In approximately 2 months, Compugen has returned 31.03% as of today's recent price of $7.03.
CGEN: 6.95 (+0.16)
Compugen Achieves Preclinical Milestone in Cancer Immunotherapy Collaboration With Bayer
PR Newswire - Mon Apr 18, 6:14AM CDT
Compugen Ltd. (NASDAQ: CGEN ), a leading predictive drug discovery company, announced today that it has achieved a first preclinical milestone for CGEN-15022 pursuant to its cancer immunotherapy collaboration with Bayer. The collaboration provides for the research, development, and commercialization of antibody-based cancer therapeutics against two novel Compugen-discovered immune checkpoint regulators, CGEN-15001T and CGEN-15022.
CGEN: 6.95 (+0.16)
Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew Pardoll Appointed Director at Compugen USA, Inc.
PR Newswire - Wed Apr 06, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, announced today that Elliott Sigal, M.D., Ph.D., former Executive Vice President and Director of Bristol-Myers Squibb, has joined Compugen Ltd. as a strategic advisor. The Company also announced that Drew Pardoll, M.D., Ph.D., Abeloff Professor of Oncology, Medicine, Pathology, and Molecular Biology and Genetics and Director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Sidney Kimmel Cancer Center at Johns Hopkins University of Medicine, and Chairman of Compugen's Scientific Advisory Board, has in addition joined the Board of Directors of Compugen USA, Inc., Compugen Ltd.'s wholly-owned antibody discovery and development subsidiary.
CGEN: 6.95 (+0.16), BMY: 72.31 (+1.06)
Compugen to Present at the Jefferies Immuno-Oncology Summit in Boston
PR Newswire - Mon Mar 28, 6:00AM CDT
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Anat Cohen-Dayag, Ph.D., President and Chief Executive Officer of Compugen, will present an overview of the Company's immuno-oncology programs and underlying predictive discovery capabilities at the Jefferies 2016 Immuno-Oncology Summit in Boston, on Thursday, April 7, 2016.
CGEN: 6.95 (+0.16)
Type-1 diabetes (Juvenile Diabetes) Pipeline Review, H2 2015
M2 - Tue Feb 09, 8:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/4jtbk6/type1_diabetes) has announced the addition of the "Type-1 diabetes (Juvenile Diabetes) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type-1 diabetes (Juvenile Diabetes)and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Type-1 diabetes (Juvenile Diabetes)Overview - Therapeutics Development - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Overview - Pipeline Products for Type-1 diabetes (Juvenile Diabetes)- Comparative Analysis - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Therapeutics under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Type-1 diabetes (Juvenile Diabetes)- Products under Development by Companies - Type-1 diabetes (Juvenile Diabetes)- Products under Investigation by Universities/Institutes - Type-1 diabetes (Juvenile Diabetes)- Companies Involved in Therapeutics Development Companies Mentioned - 35 of the 100 Companies - 4SC AG - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - AntriaBio, Inc. - Aphios Corporation - Araim Pharmaceuticals Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - Astellas Pharma Inc. - AstraZeneca Plc - Athersys, Inc. - Axxam SpA - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioLingus AG - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Caladrius Biosciences, Inc. - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Daewoong Pharmaceutical Co., Ltd. - Dance Biopharm Inc. - Diabetology (Products) Ltd - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A. - DoNatur GmbH - Effimune SAS - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/4j...1_diabetes
AMBX: (), LLY: 73.07 (+0.50), BIOD: 0.33 (+0.02), CLBS: 0.52 (+0.03), ARGS: 5.46 (-0.14), AZN: 28.70 (+0.06), CGEN: 6.95 (+0.16), ATHX: 1.95 (-0.21)
Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results
PR Newswire - Tue Feb 09, 6:09AM CST
Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the fourth quarter and year ended December 31, 2015.
CGEN: 6.95 (+0.16)
